Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer
Li-Yue Sun,Wen-Jian Cen,Wen-Ting Tang,Ya-Kang Long,Xin-Hua Yang,Xiao-Meng Ji,Jiao-Jiao Yang,Ren-Jing Zhang,Fang Wang,Jian Yong Shao,Ziming Du +10 more
TLDR
In this paper, the authors explored the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non-small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD-1/PD-L1 therapy), combined with chemotherapy or anti-angiogenesis therapy.Abstract:
BACKGROUND This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non-small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD-1/PD-L1 therapy) combined with chemotherapy or anti-angiogenesis therapy. METHODS We conducted a retrospective analysis of NSCLC patients who underwent next-generation sequencing test (either 295-gene panel NGS or 1021-gene panel NGS) from September 2017 to November 2020. The relationship between TMB and smoking status was investigated. Kaplan-Meier survival analysis was used to compare progression-free survival (PFS) of the NSCLC patients who received combination immunotherapy grouped by TMB value and smoking status. RESULTS We enrolled 323 cases and 388 cases of NSCLC patients in the 295-gene panel cohort and 1021-gene panel cohort, respectively. Positive correlation between TMB and smoking status was found in lung adenocarcinoma, but not in lung squamous cell carcinoma. Participants with both high TMB and smoking status who received immune checkpoint therapy combined with chemotherapy or anti-angiogenesis therapy had longer PFS than other participants (p < 0.05). CONCLUSIONS The combination of TMB with smoking status might be a potential predictor for the efficacy of combination immunotherapy in advanced NSCLC.read more
Citations
More filters
Journal ArticleDOI
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Journal ArticleDOI
Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study
Lianxi Song,Fei Zhou,Tian Xu,Liang Zeng,Qing Xia,Zhan Wang,Li Deng,Yizhi Li,Haoyue Qin,Zhe Huang,Jinye Mi,Qinqin Xu,Nong Yang,Caicun Zhou,Yongchang Zhang +14 more
TL;DR: In this paper , the anti-tumor activity of pembrolizumab plus chemotherapy in advanced LCC and LCNEC patients was evaluated, showing that this regimen could serve as a treatment option for improving the survival outcomes.
Journal ArticleDOI
Mutational Signatures as Sensors of Environmental Exposures: Analysis of Smoking-Induced Lung Tissue Remodeling
Yoo-Ah Kim,Ermin Hodzic,Bayarbaatar Amgalan,Ariella Saslafsky,Damian Wojtowicz,Teresa M. Przytycka +5 more
TL;DR: It is shown that a joint computational analysis of mutational signatures derived from sequenced tumor samples, and the gene expression obtained from control samples, can shed light on the combined impact that smoking and tumor-related micro-environments have on gene expression and cell-type composition in non-neoplastic lung tissue.
Journal ArticleDOI
AIM2 upregulation promotes metastatic progression and PD‐L1 expression in lung adenocarcinoma
Jing Quan Zheng,Che Hsuan Lin,Hsun Hua Lee,Wei-Ming Chang,Li-Jie Li,Chia Yi Su,Kang Yun Lee,Hui Wen Chiu,Yan Lin +8 more
TL;DR: The results showed that the mRNA levels of absence in melanoma 2 (AIM2), one of the inflammasome members, are extensively upregulated in primary tumors compared to normal tissues derived from the TCGA lung adenocarcinoma (LUAD) database, and Kaplan-Meier analysis demonstrated that a higher mRNA level of AIM2 refers to a poor prognosis in LUAD patients.
Journal ArticleDOI
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC
TL;DR: In this article , the authors identify 53 patients with BRAF mutation-positive NSCLC diagnosed between 2018 and 2022 from the Glans-Look Lung Cancer Research database and included in this analysis.
References
More filters
Journal ArticleDOI
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,Flávia De Angelis,Manuel Domine,Philip Clingan,Maximilian J. Hochmair,Steven Francis Powell,Susanna Y.-S. Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Belén Rubio-Viqueira,Silvia Novello,Takayasu Kurata,Jhanelle E. Gray,John Vida,Ziwen Wei,J. Yang,Harry Raftopoulos,M. Catherine Pietanza,Marina Chiara Garassino +28 more
TL;DR: In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum‐based drug resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
TL;DR: A graphical method is developed, the X-tile plot, that illustrates the presence of substantial tumor subpopulations and shows the robustness of the relationship between a biomarker and outcome by construction of a two dimensional projection of every possible subpopulation.
Journal ArticleDOI
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Julien Mazieres,Barbara Hermes,Filiz Çay Şenler,Tibor Csőszi,Andrea Fülöp,Jerónimo Rodríguez-Cid,Jonathan Wilson,Shunichi Sugawara,Terufumi Kato,Ki Hyeong Lee,Ying Cheng,Silvia Novello,Balazs Halmos,Xiaodong Li,Gregory M. Lubiniecki,Bilal Piperdi,Dariusz M. Kowalski,Keynote Investigators +22 more
TL;DR: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus pac litaxel or nab‐paclitaxel resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann,Tudor-Eliade Ciuleanu,Adam Pluzanski,Jong-Seok Lee,Gregory A. Otterson,Clarisse Audigier-Valette,Elisa Minenza,Helena Linardou,Sjaak Burgers,Pamela Salman,Hossein Borghaei,Suresh S. Ramalingam,Julie R. Brahmer,Martin Reck,Kenneth J. O'Byrne,William J. Geese,George Green,Han Chang,Joseph D. Szustakowski,Prabhu Bhagavatheeswaran,Diane Healey,Yali Fu,F. E. Nathan,Luis Paz-Ares +23 more
TL;DR: The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD‐L1 expression level of at least 1% and those with a level of less than 1%.
Journal ArticleDOI
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone,Martin Reck,Luis Paz-Ares,Benjamin C. Creelan,Leora Horn,Martin Steins,Enriqueta Felip,Michel M. van den Heuvel,Tudor-Eliade Ciuleanu,Firas Benyamine Badin,Neal Ready,T. Jeroen N. Hiltermann,Suresh G. Nair Md,Rosalyn A. Juergens,Solange Peters,Elisa Minenza,John Wrangle,Delvys Rodriguez-Abreu,Hossein Borghaei,George R. Blumenschein,Liza C. Villaruz,Libor Havel,Jana Krejci,Jesus Corral Jaime,Han Chang,William J. Geese,Prabhu Bhagavatheeswaran,Allen C. Chen,Mark A. Socinski +28 more
TL;DR: Nivolumab was not associated with significantly longer progression‐free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD‐L1 expression level of 5% or more.
Related Papers (5)
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Giannis Mountzios,Epaminontas Samantas,K. Senghas,E. Zervas,Johannes Krisam,K. Samitas,Farastuk Bozorgmehr,J. Kuon,Sophia Agelaki,Sofia Baka,Ilias Athanasiadis,L. Gaissmaier,M. Elshiaty,L. Daniello,A. Christopoulou,Georgios Pentheroudakis,E. Lianos,Helena Linardou,Katharina Kriegsmann,Paris Kosmidis,R. El Shafie,Mark Kriegsmann,Amanda Psyrri,C. Andreadis,Elena Fountzilas,C.P. Heussel,Fjf Herth,Harland S. Winter,Christos Emmanouilides,Georgios Oikonomopoulos,Michael Meister,Thomas Muley,Helge Bischoff,Z. Saridaki,E. Razis,E.-I. Perdikouri,A. Stenzinger,I. Boukovinas,Martin Reck,Kostas N. Syrigos,Michael Thomas,Petros Christopoulos +41 more